

## Corrigendum to “Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review” [New Microbes New Infect] 6 (2015) 1–4]

N. Wagner<sup>1</sup>, C. A. Wyler-Lazarevic<sup>1</sup>, S. Yerly<sup>2</sup>, C. Samer<sup>3</sup>, G. Peytavin<sup>4</sup>, K. M. Posfay-Barbe<sup>1</sup>, A. Calmy<sup>5</sup> and J. Ambrosioni<sup>5,6</sup>

1) Department of Paediatrics, 2) Laboratory of Virology, Department of Genetics and Laboratory Medicine, 3) Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva, Switzerland, 4) Department of Clinical Pharmacology-Toxicology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France, 5) Division of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland and 6) Infectious Diseases Department, Hospital-Clinic-IDIBAPS, Barcelona, Spain

**Corresponding author:** N. Wagner, Unité des maladies infectieuses pédiatriques, Département de l'enfant et de l'adolescent, Hôpital des Enfants, Hôpitaux Universitaires de Genève, Rue Willy-Donzé 6 - 1205 Genève, Switzerland

**E-mail:** [noemie.wagner@hcuge.ch](mailto:noemie.wagner@hcuge.ch)

The authors regret that in the original version of the article, for all drugs dosages that are written as ‘four time a day’ should be written as ‘once a day’ (4 time a day = qid/1 time a day = qd).

The authors would like to apologise for any inconvenience caused.